Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • ‘As bad as it gets’: Donald Trump’s New York business empire imperilled by fraud ruling
    • Obesity drugmaker’s expansion raises dominance worries for Denmark
    • New York immigration crisis exposes tensions among Democrats
    • Absent Donald Trump draws fire from Republican rivals
    • Donald Trump committed ‘repeated’ fraud by inflating real estate value, New York judge rules
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Adani switches UK auditor to firm with four partners  
      • Dealmaking languishes at decade low on private equity drought
      • US private equity firm takes stake in Liverpool Football Club
      • UBS seeks last-ditch settlement in Credit Suisse ‘tuna bonds’ case
      • Jailed oligarch accuses TPG of colluding with Kremlin to seize $14bn assets
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news: US mortgage rates hit highest level since 2000
      • Fed’s ‘higher for longer’ message hits US stocks and bonds
      • A power grab against private equity threatens the US economy
      • European bond market hit by Italy’s plans for higher borrowing
      • UK regulator to launch review of private market valuations
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A power grab against private equity threatens the US economy
      • Francis Drake’s swashbuckling spirit lives on in Kyiv’s Black Sea battles
      • Rishi Sunak’s new strategy exposes 13 years of Tory failure
      • A strategy for hard-pressed consultants
      • What the world should expect from a second Trump term
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Success is more complicated than one exceptional individual
      • Paternity leave in finance: ‘The more men do it, the less of a big deal it becomes’
      • The activist sued by Elon Musk: ‘We have to show we will not be cowed’
      • What Burberry taught me about the marketed mind
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Why Linda Yaccarino took on the wildest job in Silicon Valley
      • Horizon 22 trumps the Shard to become London’s highest viewpoint (and it’s free)
      • Booker Prize 2023: the shortlisted titles reviewed
      • Democracies need to work quicker and smarter. Here’s what that might look like 
      • On the ranch with Ralph Lauren
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Merck & Co Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 25 September, 2023
      Coronavirus treatment
      Covid antiviral drug linked to ‘transmissible’ mutations, research finds

      Big-selling molnupiravir treatment produces permanent mutations that can be passed from patient to patient

      An experimental COVID-19 treatment pill, called molnupiravir
    • Tuesday, 29 August, 2023
      US politics & policy
      US targets 10 drugs for pricing negotiations in crackdown on costs

      Expensive medicines made by Pfizer, J&J and Merck selected for talks in biggest shake-up in decades

      A pharmacist holds a bottle of the drug Eliquis,  sold by Bristol Myers Sqibb and Pfizer
    • Tuesday, 6 June, 2023
      Merck accuses US of ‘extortion’ in lawsuit against drug price controls

      Pharmaceutical group says parts of law are unconstitutional

      A Merck logo
    • Monday, 17 April, 2023
      Lex
      Merck/Prometheus: Big Pharma must swallow bigger premiums Premium content

      Pharmaceutical giant has good reason to gamble on acquisition before blockbuster drug loses its patent protection

      Outdoor signage at Merck headquarters
    • Sunday, 16 April, 2023
      Mergers & Acquisitions
      Merck buys Prometheus Biosciences for almost $11bn

      Pharmaceutical and biotech deals are rebounding after a dip last year

    • Sunday, 26 February, 2023
      Pharmaceuticals sector
      Big Pharma fights patent disclosure demand from investors

      Industry rejects call for transparency over use of strategy that can delay competition from generic medicines

      Bottle and package of Merck’s Keytruda
    • Friday, 23 December, 2022
      LexDrugs research
      Medicines: triumph of science in 2022 is worth celebrating Premium content

      From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances

      Merck’s Keytruda medication
    • Thursday, 22 December, 2022
      Coronavirus treatment
      Merck antiviral trial shows promising impact on Covid recovery time

      Results of UK study show drug cuts symptom duration by about 4 days but does not reduce deaths

      Molnupiravir capsules
    • Tuesday, 13 December, 2022
      Drugs research
      Moderna’s mRNA cancer vaccine shows promise in early trial

      Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients

      Moderna’s logo is reflected in a drop on a syringe needle
    • Thursday, 6 October, 2022
      Coronavirus treatment
      Merck Covid antiviral pill did not cut hospitalisation risk, study finds

      UK trial shows ‘no difference’ between taking molnupiravir or placebo in reducing clinical admissions during Omicron wave

      Merck’s molnupiravir  pills
    • Sunday, 7 August, 2022
      Pharmaceuticals sector
      Merck defends tax approach against senator’s claims of avoidance

      Chief financial officer says drugmaker complies with law amid congressional probe

      The Merck corporate headquarters in Kenilworth, New Jersey
    • Friday, 8 July, 2022
      Lex
      Merck/SeaGen: regulatory hurdles will be tough to clear Premium content

      Tie-up faces obstacles in current climate of aggressive watchdogs and concern over drug prices

      Test tubes at a Seagen facility
    • Thursday, 7 July, 2022
      Pharmaceuticals sector
      Merck in talks over $40bn deal for cancer biotech SeaGen

      US group attracted by approved drugs as it prepares to lose patent protection of Keytruda

      Outside Merck’s headquarters in Kenilworth, New Jersey
    • Wednesday, 16 February, 2022
      Coronavirus treatment
      Merck struggles to win European approval for Covid antiviral pill

      EMA said to be unlikely to grant marketing authorisation to molnupiravir this month after ‘problematic’ data

      Molnupiravir capsules
    • Wednesday, 22 December, 2021
      Covid-19 vaccines
      France cancels order for Merck antiviral tablet on efficacy fears

      Concerns grow over molnupiravir’s ability to reduce Covid hospitalisations and deaths

    • Sunday, 5 December, 2021
      Coronavirus treatment
      Merck takes aim at Pfizer’s Covid pill as concerns linger over its own drug

      Executive says patients on other medications will not be able to take competing antiviral treatment

      Merck’s molnupiravir antiviral drug
    • Tuesday, 30 November, 2021
      Coronavirus treatment
      Merck’s Covid pill secures narrow backing from US regulatory panel

      Experts advising FDA recommend treatment for high-risk patients amid fears over Omicron variant

      Merck’s Covid-19 treatment pills
    • Friday, 26 November, 2021
      Coronavirus treatment
      Merck says its Covid antiviral treatment less effective than first thought

      Full analysis of trial results shows molnupiravir had a risk reduction of 30%

      Molnupiravir capsules
    • Friday, 12 November, 2021
      The Big Read
      The Covid drugs are finally here

      New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?

    • Thursday, 4 November, 2021
      Coronavirus treatment
      Merck’s Covid pill Lagevrio secures green light from UK regulator

      First authorisation for antiviral drug that halves risk of hospitalisation or death

      A doctor holding a molnupiravir pill
    • Wednesday, 27 October, 2021
      Coronavirus treatment
      Merck signs royalty-free deal to expand access to its Covid-19 pill

      Move contrasts with mRNA makers Pfizer and Moderna, which have rejected sharing vaccine technology

      The Covid-19 treatment pill molnupiravir that was developed by Merck and Ridgeback Biotherapeutics
    • Tuesday, 12 October, 2021
      LexCoronavirus treatment
      Coronavirus pill: Merck forges a new hammer to crack pandemic Premium content

      Molnupiravir has limitations but drugmakers should be able to build on it to create other treatments

      Tablets of Merck’s molnupiravir
    • Tuesday, 12 October, 2021
      Coronavirus treatment
      Merck aims to double supply of Covid-19 antiviral pill on rising demand

      Drugmaker seeks authorisation from FDA for oral treatment shown to prevent severe disease in vulnerable people

    • Wednesday, 6 October, 2021
      News in-depthPharmaceuticals sector
      Merck on deals hunt as patent cliff looms for top cancer drug

      Investors fret over how company will fare when Keytruda loses exclusivity

      Merck corporate headquarters in Kenilworth, NJ
    • Friday, 1 October, 2021
      Coronavirus treatment
      Merck says Covid antiviral pill halves risk of hospitalisation and death

      US pharma group seeks authorisation for first drug of its kind after ‘remarkable’ clinical trial

      Molnupiravir pills
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In